WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS PLC TO LAUNCH NAMED PATIENT USE PROGRAM FOR TEPEZZA® (TEPROTUMUMAB-TRBW) Read More 18th May 2021
WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS Read More 25th March 2021
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB® Read More 1st March 2021
WEP CLINICAL PARTNERS WITH US BIOTECH COMPANY FOR THE NAMED PATIENT SUPPLY OF CANCER PRODUCT IN EX-US COUNTRIES Read More 24th August 2020
WEP CLINICAL PARTNERS WITH BTG SPECIALTY PHARMACEUTICALS FOR EUROPEAN SUPPLY OF VORAXAZE® Read More 1st July 2020
WEP CLINICAL PARTNERS WITH NABRIVA THERAPEUTICS FOR THE NAMED PATIENT SUPPLY OF XENLETA® (LEFAMULIN) Read More 30th June 2020
